NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Buyer
NHS England
Value
£4,108,145,000
Published
29 Jul 2025
Closes
7 Apr 2025
Procurement details
Source
Find a Tender
Region
United Kingdom
Procurement method
Open
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33600000
Pharmaceutical products
Lots
Lot 1 Lot 1 - CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East
£2,848,328,000
Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027. Additional information: Price is not the only award criterion and all criteria are stated in the procurement documents.
Delivery: United Kingdom
Lot 2 Lot 2 - CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE
£26,389,000
Eculizumab and Ravulizumab for London & SOFE. Additional information: Price is not the only award criterion and all criteria are stated in the procurement documents.
Delivery: United Kingdom
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.